EYEN - Earnings call transcript Q4 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings, welcome to Eyenovia's Fourth Quarter and Full Year 2020 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note this conference is being recorded. I will now turn the conference over to your host, Eric Ribner.

begin. may You

Eric Ribner

everyone Sean and Michael conference the everyone, results are on ended to well which Eyenovia's months XX, quarter issued Eyenovia's release annual December Officer, fourth the December Chief Officer, press Chief Good the few also Gandolfo; with release, report We encourage SEC a Earlier John be and welcome XX, filed the today's XX website this as audio for earnings and and Dr. next read Medical Chief call Officer report will Operating and today financial days. and webcast. as on XXXX Eyenovia's three XXXX. press Eyenovia's eyenovia.com. Form year Executive XXXX, annual at company's Financial Officer, afternoon, Eyenovia's The be Chief release and to Ianchulev; available Rowe. With announcing Eyenovia's within XX-K will Eyenovia me afternoon, for ending press

addition, of like that to, at FDA potential in accurate materially In associated this These that our results of circumstances by archived that differ risk and under our and the With during to could in and as product to our after as to to Please update a management including yet call, COVID-XX rate products raise of to to or of to to global timing XX required risks, submit law. may platform for Dr. a and contains evolving adversely Eyenovia's receive is reference. for call, in said, the least the and light of have applicable our call the volatility platform also company's and reflect XX-K or impacted XXXX. trials. Form through going qualified statements forward-looking fluctuations with ability ability to economy is turn candidates, annual those report of clinical obligation pandemic, and our We our uncertainty and Private XX, Ianchulev. Please its on the attract we and future our no Actual March SEC product number fund Eyenovia's time-sensitive for and and will candidates, and trials maintain cautionary and covered forward-looking the ability related cost, to business. Harbor be results webcast note social to technology caution for but regarding website, and timely the any the additional except intellectual candidates, enrollment recent concern, risks distancing, our by will marketing press related partners manufacturing, third potential by degree market of of regulatory on resulting this retain by licensing stated filings. provisions which utility forward-looking the supply impact and licenses due events being property the be of our Safe initiation, candidates our This listeners timing, our those Securities not and most I'd technology, money financial Litigation opportunity of certain is today's risks that key the candidates this estimates filings, obtain advantages the uncertainties the or product be our and including, and progress, statements which and release Eyenovia statements. potential Sean revenue date technology on in company's as Act. limited COVID-XX making of could from personnel, securities Reform only information product financial implied the discussing undertakes from clinical and capabilities and of the be statements implement, licenses other applications next are broadcast, be COVID-XX market markets maintain acceptance call, product for, results, and in The our commercialization, design, to date information platform strategies will and of revise the such our call chain, and operations investigational contained conference risks reliance including conference months the note live risks, discussed and potential subject over need parties, the to subsequent us forward-looking approval. on for this statements call all call today conference our develop, on that transactions, approvals

Sean Ianchulev

Eric. you, and fourth call. conference earnings everyone Thank year XXXX And to our welcome quarter full

it becoming ophthalmology. proprietary quarter of field announced fourth applied transition for exams leader million the the precision would each clinical we our smart a commercial mydriatic combination During application and MydCombi – with made progress system, the a fixed and year towards our in we Most FDA into eye proprietary potential in more programs the significant XX the advancing would, us our stage that only currently be MydCombi, United in the it microdosed recently be the for recognized approved not our drug accepted recently, would Optejet, first conducted ocular company. new delivery proprietary notably, use over States. but comprehensive If therapeutic high

a elaborate market targeted on field and network. shortly. this specialty and given XXXX will Michael for MydCombi of combination can pharmacy been have XX, with We MydCombi October we in with approved, a highly salesforce PDUFA date and if effectively and we small expected efficiently believe

year we're quarter XXXX. enrolled the that track first deliver VISION-X is near presbyopia, in study the second fully happy also of I'm formulation, top-line our improvement patients delivered to is and pilocarpine We MicroLine, the on been had in X earlier VISION-X for that proprietary of results via announce announced this in now our evaluating also dosed vision patient Optejet, clinical with Phase which to the

vision. As and a the the Canada. affects myopia eyeglasses, reminder, Bausch impairment is blurred XXX clinical that corrected We that surgery. opportunity has is begins in Recall for or hardening million contact estimated in often causing XX believe the been Vision the third has near more the market Health typically lens a age-related of MicroPine after presbyopia readers, people MicroLine with U.S. the of presbyopia age significant our lenses pediatric program than it's licensed U.S. out reduction alone. of that in and to eyes progression

provide hand point, a creating ophthalmologic once date, South have increase second MicroPine, Phase established. X to non-dilutive license our multiple potential as one NDA enrolled $XX accepted, pleased leaders over of potential MicroLine I Michael some total with our as and in I'm to fees call outlicensed to as highlights program entered like well Michael? partnerships or robust milestones. well non-sales this the now At value program. approximately related well have and with partnerships Arctic greater cost Korea. gross fully the Vision generated a approximately these line initiated from as milestones, of with MydCombi reimbursement as XXXX momentum have sight progress to very upfront we To several account. savings non-dilutive addition, and $XXX to development we in would million capital to of as clinical believe million China with year and taken to In potentially and With to last into significant milestone-based

Michael Rowe

Sean. Thanks,

As Sean indicated, we our has recently the MydCombi. accepted FDA announced that NDA for

requires which want technology via mydriatic many of minutes XX% This our that and upon our of MAP Optejet they patients time eye array found multiple eye at Our or pharmaceutical apart. microdose that pupil pupil dilation research given agents considerable eye The current situations undergo dilation least standard uncomfortable procedure. can to for exam, an as skip take because print often drug the cause drops as encounter proprietary reported dispensers base. care administered both Prior do discomfort and several they comprehensive where has overflow. providers care not

process there should comprehensive have to more believe help everyone the for is a significant make is exam that who get we pupil dilation So need sure to improved one. of willing

the a dilation micro-dosed combination published minutes pharmacologic delivery, in site which of Approximately dilation the MIST-X online help XX and pupil with study patients. met be instillation chance related Phase a conventional of format. fewer pain. MydCombi was parts a to primary two photophobia the shown were phenylephrine of of developed pupil providing was touching were the The reduced reporting an MIST-X was Additionally, greater is tropicamide of with ophthalmic post-instillation. and peer-review X and Optejet greater in of between the these mydriasis. of improve combination events usual may help studies. practice based access the the at designed to solution the X% X.X% achieved of therapeutic open acuity, age or protruding studies’ available across and patients. than safe microdose infrequent, the journal of in to is and formulation, surface Adverse the In the ocular blurred X% touchless vision, The fixed effective mm fixed cross-contamination eyes process there for of sensitivity goal accidental droppers dilation COVID-XX, NDA results to and or process. on reduce treated patients with submission MydCombi endpoints studies, recently to number XX% hygiene The are X the medication sharing no of efficiency of prevent designed improve

commercial of an come expected our U.S. measured October XX, and infrastructure. investments have MydCombi for date in received have PDUFA We XXXX

used it typically be The We or would I the MydCombi launch doctors it streamlined and launch here nor that practice are sales mean reimbursement. eliminate data. to If large making and exams. It recently to require through e-commerce and some that force is sales EVERSANA by XXX will highly about when would all and cases on individual in an not is which related like commercial patients, commercial announced a commercial detailing, our the our of explain purchased dependent if conventional moment diagnostic behalf receive pharmaceutical infrastructure. a take is efficient And to in what for agreement use MydCombi. our with a significant by we need can designing is of prescribed a salespeople of distributed time product successful, MydCombi practice. efficient, of and launch formulary our on system real be we approval. is in acceptance through

force launch hand our the launch, will process. of practices and planned the MydCombi We who of practices in addressable commercial in their get expect have to XXXX. XX% into we our the and further on to market largest possible. ready U.S. the population launch as to approximately centers sales quickly U.S. patient XX expand we account day by incorporated estimate largest be other approximately can end plan that With have as our managers the focus the the volume on led on once by capturing those so our We work can we efficiently and

comparable MydCombi's We [indiscernible] the organizations the MydCombi also patient to This At be and compelling. proposition our forward commercial million MydCombi than in to significant offices they own will account the improve commercially drops exam disrupt we FDA bottom Needless milestone that reach year. MydCombi over potential with to our we presence first for and cost significant to turn would to for help distribution office ophthalmologist approved, are greater reduced like the coupled market, to conventional I'd with with a later our prepare it product be a can we that a to $XXX turn believe our of value spending strategy are worth be a could augment that to doctors what the already today time look of If very resulting estimate to comprehensive the about meeting line. these work rollout. our we company. throughput. back this believe use say, is is managers optometrist highlighting targeted of value proposition With with the eye success that It available will and exploring patient into potentially MydCombi, chair have doing. of partnerships Sean. are excited We what in and practices the approximately drive faster or

Sean Ianchulev

you, Michael. Thank

and The microdose for medication. comparable new eye and successfully can our fewer Optejet quarter, eye. multiple proprietary that are the that both unwanted as delivery like technology preservatives are very may microdosing eye step and approximately drug who approximately printer leading on Optejet by exposure technology XX% and with of to administer on Optejet of side We than the to to inkjet that able of I eye found horizontal did successfully administer be utilizes on effects similar the has much to achieve half delivery our physiologically show eyedroppers, of overdose XX% the a attempt. first drops compares where Optejet. favorably to attempt. patients array story. to believe the comfortable shown start back As that users administer using optimal have Studies drug to a compatible shown to for harmful. studies efficacy been to clinicians Prior XX% less medication patients clinicians drops were the and using This can able medication first last an designed to access fourfold, published dose I studies as be to cornea would conventional is print eye. unnecessary to the It take those to

of in to review product China, estimated announced improvement I million with our MicroLine program interest end the intend year XXX XXXX. dose presbyopia lens contact potentially people adult the the this to causing surgery. the the Currently, of or and for determine in we of We financials, which have option with the data focus the of anticipate presbyopia. X drug with further gradual John assess like to more the subject the ocular of eyeglasses, and ability growing sometime and Presbyopia, a on recently in U.S. where people of turning initiation affects near of the vision there age-related for test with of would eyes hundreds for already plan the factors hardening we in call presbyopia. to VISION-X higher are objects depending the if the treatment to millions the review to pilocarpine to nearby the is an the licensed conclude Arctic study Phase Before in which Vision. follow to QX of tolerability in non-preventable by other COVID-XX dealing and initiation There We only up is response. lenses is in VISION-X loss

Our this in target shows product development near eyedroppers; sets estimate market demand is other eyeglasses. targeted U.S. provide we increased technology potential and If a treatment conventional could our an in and apart technology companion the the believe MicroLine our prefer high improvement now overdosing for very research enrollment exciting approved, believe for vision is This times significant. to market be $X we the by our those Optejet. John? with program. vision. safety whose an VISiON-X. among in a to in common turn dispensing initiated own be MicroLine facilitate billion. like pilocarpine over differentiators is are of call portability, advance eyeglasses therapists. to In among been opinion drug be of the offered is when is vision on-demand and in We to on we're improvement improving near program the accurate that BI market The for efficacy pleased John us, our as our not will us have review financials. compound Pilocarpine would patients we interest administer would may I'd as to excess Optejet comfort, competition for wear a a without used the alone has opportunity to important my a to near century-old company's what well-documented, from to

John Gandolfo

Thank you, Sean.

like XX, ended financial for three December our XX XXXX. the Now to I would results and review months

or compares $X.XX quarter of and net XXXX. share of $X.X or per per of quarter fourth $X.XX this of loss we net approximately the reported a to million a million loss fourth for share For XXXX, $X.X the approximately

recognize loss year million. full this a $XX.X XXXX year $X.XX was million for and For milestone related XXXX. represents approximately full the a $XX.X compares full the per loss collaboration revenue in same Research August net of to $X.X or approximately $X.X revenue the to fourth XXXX. net of approximately totaled payment or approximately Vision, announced XXXX did of with in $X expenses a and with quarter full $X.XX roughly for XXXX; million flat any the year not period the fourth fourth of quarter share and XXXX. exclusive for either which and million Revenue We development million our license Arctic to per XXXX. agreement was of share for in year the This or was loss quarter

$XX.X this X% and million approximately to the For or the XXXX decreased R&D year for compares full year million, XXXX. full expenses $XX.X

an compared XXXX, X%. For the XXXX for approximately quarter were of million fourth the approximately quarter $X approximately of of increase million expenses $X.X G&A fourth with

administrative $X.X This the compares operating full of million million, operating and to compensation $XXX,XXX versus full expenses included expenses $X.X year X%. to same XXXX and of period expenses represents XXXX. approximately general approximately for For $X.X this million expenses expense. the year fourth XXXX the increase the approximately for were non-cash million stock quarter total for XXXX. of of $X.X increased X% XXXX, of Fourth operating an quarter Total

the to operating of $X.X approximately $XX approximately total stock $XX.X for million million operating compensation year year XXXX, For expenses non-cash full X% expense. decreased included the XXXX. million XXXX compared expenses full of

milestone XXXX, company's and balance approximately first the We cash this XX, as received As XXXX balance million. believe in of cash payment, of quarter cash as $XX.X from was the well December the quarter our NDA launch. exercises and middle MydCombi, XXXX, Warren the of enable out commercial and to product to Mydriasis' process of will through sufficient us into the the is last first bring us

for pilot clinical remarks. preparing concludes financial and for our our This technology. dispenser completing the program addition MicroLine to manufacturing advanced capabilities In statement presbyopia

to over Sean? back like to the So, call Sean. I'd turn

Sean Ianchulev

summarize, we October we highlights our product. and year during MydCombi our you, To were today approved key and our performance pleased us anticipate on subsequent XXXX, fourth XX, the our which quarter In full with Thank commercial PDUFA closing, for date John. XXXX very period. gives NDA, first if you. Thank

believe Phase And Arctic realized in near meaningful presbyopia very studies dollar data to the we positioned from we and development with an We long-term things other our value milestones. Vision our estimated program if progressing That and that and expand remarks. multi-billion Novel to development advancing in the and the We call X creating our XXXX, at aimed plan our term. advance Phase open multiple to are technology. to in prepared to rapidly Health our potential to and X leveraging like offer well use commercial, pipeline funding Bausch well questions. of anticipate agreements Therapeutics are our regulatory Non-diluted for Operator? licensing first of regulatory our concludes catalysts indication We among MAP shareholders. continue would and any now two for are achieve

Operator

Our Instructions] proceed question is [indiscernible]. your [Operator question. first Please with from

Unidentified Analyst

Hi, you're study with there thanks. in endpoint, VISION-X be any here to study secondary this well will that able present to data outcome measuring John, the study when in as is you quarter addition in second of any the measures are primary complete? this and that

John Gandolfo

Yes.

a repeat collecting to to we any your guess primary it it are additional for have the in or I collecting end yes, points hear the question think just And I lot it data. hope of So is we data? little hear, can addition answer points whether faint a to we're was everybody. other whether everybody is, end I

this exploratory see of will are Phase two for wealth the to points provide This X/X X, the we you as does Optejet. points anticipating trial with with as is data end and and that Again, a well. really data doses a how know, Phase secondary study have We end us.

VISION-X VISION-X from We the able before the quite we in to be informed study later with will be this proceed year. study

that present just answer question we'll how data? the with yes. your to now to is strategy. We the about; will have when So And publication prices yes, our see

our Of and course with be not done will them. this registration probably ahead probably synchronization in efforts of

Unidentified Analyst

be in in October guys just most one you At the salespeople PDUFA will think or before that data, bring that? quarter the likely do third what it will MydCombi I I – the point think And specialized maybe XXth. need today, see. probably follow-up be on announced you to sales will you

Sean Ianchulev

Michael think advantages therapeutic, of blasting to is we're plan let so his launch XX one-by-one how traditional with on of people doctor one would one typical only some where from we this this. yes, a will a I'll have ophthalmology, This educate do allow Yes, articulated, I prescribed folks patient. all and not to way. in think – to probably launch the us is you overhead. it's this but really reps, a have distribution to I really But to other it go here. to a really very let effective commercialization out to the confessional we in cost really parts was one going really presentation force, not And sales about Michael bring where cost companies because partially not your Most big where purchasing it commercial do mass in today would

We we that a at go are may do the technology, and down would two market a introduce cost at prime way. the but very time this be years is as justified, same efficient MydCombi MicroLine it the to towards really happen down when way later in not looking perfect where this

can you answer Michael, maybe in more that detail. So

Michael Rowe

the anticipate time September so for at and that to we on using for with they that August, get that and to the anybody it affairs potential get be only here the for uptake. August, August October. work is in end to the becomes be onboard approval And faster bringing September add thing technology educate would customers before start I us would of do when them would the be approval we the that here. Well, people Tim our we don't preparation medical much to

Unidentified Analyst

to data seeing thanks forward very quarter in much. look on the and the second Okay, MicroLine great. Well,

Sean Ianchulev

you. Thank Certainly.

Operator

And Ladenburg. your question. Matt is with from Kaplan question with our proceed next Please

Matt Kaplan

the questions, for for thanks maybe question I a the taking starting progress. guess, off, and Hey recent on congrats Michael. guys,

recent of October, of sense MydCombi As for a the and your agreement with marketing that plan strategy you're how prepare kind into commercial of give as at terms plans nearing more your can and us date end launch? fits in little to you EVERSANA you bit the PDUFA

Michael Rowe

want much the Yes. be going to infrastructure that doing and is And efficient build What to have is philosophy possible, we're for you question. not the up not to we're we thank very as all as under feed. an

invoicing with billing service shipping, they EVERSANA idea the us in having and customer is those So basically and take and save and like can that things to over house. have from things

keep a So basically will what are we they key people, once to we better a will then they need EVERSANA. online, technology, again force product specialized job cards, the of will to that. account as knowledge But which that and ordered, possible the simple it go can general sales be it use all believe do in-house about have is because would everything else not credit through as have, keep that

of we normally, in-house, or build would have that a we So ourselves. would section that have company basically won't entire what outsourcing to what normally

Matt Kaplan

of Okay. approach doctors teaching force then strategy hands-on And do in use having way you initially see that to and is officers of the a terms the very or there? approach it and your sales your kind to device what's going

Michael Rowe

the So is the we feel product. with experience need be to lot believe and it the about strategy able it do best XX to on to use how the a them hands-on, It take minutes, get but be really doesn't educate it would you to product. takes touch to

the the what they often are and dilation office they then one key the are ones and who there, So would the the the for in days. managers, to the people leave who say, who would advantages four pupil the most the do for go are use ones lunchtime evaluation and or actually that doctors they'd works with dispenser final how but our practices end likely into the they and And and be the would spend idea showing in account it. do ordering go the technicians have work three the them they'd a how that

and XX complete come So back can use delighted by be actually we'll they it the then patients because and hopefully, sale. on then

Matt Kaplan

anticipating the any and [indiscernible] VISION-X this for And then what VISION-X? and VISION-X of then Thanks. MicroLine question in in Sean, terms for timing the you're maybe plans VISION-X success shape should that versus for potential pilot study? a foreseeing are given Great. your differences indication take how And – maybe success already,

Sean Ianchulev

Yes, at Matt, and initially very you remember in planning do to background, the question maybe of this were a is before same it's terms if time. even VISION-X COVID VISION-X good we and

new little it, VISION-X I plan from at it to we think VISION-X Allergan, from rushing again, can know is actually the we studies made it lot looked a to two and also maximum there whole yet. Phase data when COVID a because compound, even bit, were really We positive indication, of X this there's learn and same we intermediates with that. sense this companies that into apply then a but haven't seen AbbVie

VISION-X the to acuity. enroll VISION-X. VISION-X indications materially enrollment the We're end demand, still improvement data QX year, is So year, the quickly get study. of of comfortable we near And the more different we in to again, from take I will really think not of initiating next starting very be by of for VISION-X wanted a visual measured The plan on here with quickly QX approach where really the and learn for to stepwise. looking

So the endpoints dose down-select We VISION-X of from the the same. a the lot may will results. depending be on

year. to COVID very So I of site Matt, the allow we I be were enroll us We a operationalize will by we this be to and very, we going that to think fully pandemic if happens, closure be exactly today. execute her phenomenal disclosed it, would to launch as will mean, end and in and able I to the And of hope it will and VISION-X. will that think able a that Ginger midst similar team a We it everything study, else. promptly job execute similar. it's did a VISION-X be hard positive a very say the except launch study do, what to

So for I enrollment. be think a hopefully we're prompt cadence, looking that similar going very a very

They're patients treatment use many and We It's patients many paradigm technology of smart. presbyopia. use new about and just something ecstatic able change a modern indication. this to really and so big redness about being about opportunity such don't the that's have have very mean, science really very eye, population. not the the dropper have so to the to I And hardware available. the overdosing in you beauty a be free for patients. There's and ecstatic where to just paradigm with eye are patient antiquated

to So VISION-X I we end really the of us, well. hopefully to and decide as the year very VISION-X think when any foresee we don't this launch results button issues for for by quick push get

Matt Kaplan

And clinical Great. impressive team, backdrop the by given execution pandemic. definitely the Thank you. your of

So congrats on that.

Sean Ianchulev

you, Matt. Thank

Operator

proceed Our Aschoff question ROTH your Capital Partners. Jonathan Please question. from with is with next

Jonathan Aschoff

Thank though about you. is Mydcombi, used wondering, any you from to off somehow in expect could were not patients, way sold it Do label still there amblyopia? being be I was that you any that individual even news talking setting?

Sean Ianchulev

Right.

when So we you first company never really encourage anyway. will used in as off amblyopia, for say a use label Mydcombi

think therapeutically the actual use by tropicamide. today, I and use is a pain combination treated fixed phenylephrine Second, way not of of amblyopia is by

know. really don't we again, So

suggest, a applications. out the such hasn't changed registration can support as the two Mydcombi may or the and really you three but a have But very very through life a I People we price think marketplace pray there. with people, And so such And transitioning as a the really as target, XXX on – we $XXX way. the experience – which I'm have a million be And to that that Eyenovia find to market, find. different patient for that. out I'm the find we'll many the pathway, single paradigm. with is are to clinicians the in of the life market. now certainly, assuming who $XXX really that the And product. be we sure a Michael how on listening we're very through pathway, discomfort lot year years them But not almost here. huge. and cycle that be section that we're price there all, understand part knows happening in market a dilations what with parity to section different exam may cycle million problems clinicians once we not every creative, of moving of re-energized in find that as in – conventional And when parity successful the doctors don't and part will it's drops can it's really and eye certainly after and which will who response is we're registration today, major a focused for a that a technologies a game-changing alleviate market, from out says dramatically

Jonathan Aschoff

– have your Actually to you how with pricing will pricing what initial Mydcombi? your be clear been

Sean Ianchulev

do Michael, address Yes. want that? to you

Michael Rowe

patients. around that Yes, spending somewhere $X, what thanks, drugs about a cartridge doctors is a a that, are two that. treat and $XXX, currently they to Jonathan. $X.X XX anticipating that are going so we're patients. and know said we've now a We close We're very at or use spending be price least the for And cartridge officers for of to should

the practice, an for an out pocket of issue. expense it not So should from be

Jonathan Aschoff

very you guys. Thank Okay. much,

Michael Rowe

You're welcome.

Operator

is next [Operator from Stoc*Doc Leonard your proceed Please Instructions] Yaffe with Partners. question. Our with question

Leonard Yaffe

first call think is you the the to very since And had you've much. that of promotion Rowe conference COO. Thank this Mr. I

a wanted endpoint improvement My vision and or just when subset low-light in the I you on similar conditions from question light a without of that in just that? be let's vision, conditions get their improvement near without distance we a of of low getting is endpoint loss So vision and VISION-X, we'd for be to results the results him. of new responsibility to commend Allergan

Sean Ianchulev

thank you. And about spirit, in And congratulations I'll Michael. really timely excited responsibility a increased Leonard, we're him for question. role let just Yes, that answer and that and the again, it's very

Michael Rowe

similar available side will The have to be top-line. have look There'll and the second be at the a by profile. presented also to we're that doctor that you, in quarter when effect going doctor. very going results to We're special Thank Allergan. been take the results

better we're history trials. tolerability. you demonstrating have And hoping and We the can looking to strong to and a being studies by get in of much that clinical able similar presbyopia that in our see using technology, effectiveness forward

headache our a to One patients. believe us a our for eye presbyopia in Optejet shows is market brow we lot ache and and back would that traditional if about an or of held of it to as product, the And eventually it's eye can encourage over pylocarpine have significantly the improve that product, that's do we research known on microdose the dropper. is XX% side things a effect drop uptake choosing that

Leonard Yaffe

very Yes, you you've I dose, was doses I comment patients secondly, drug I it's chosen, think given discomfort think a be that on that consequence, alternatives the contact revert wondering was their a that. two that I back lenses. of dosing an think that in any such but important you the eyeglasses less. presbyopia I of experiencing wondering they're can could is used there if your or need if on that likely either to of side to non-medical Allergan point deliver And is for are pilocarpine, any the

think Thank that understanding. I great So you. bears

Sean Ianchulev

would we for trade the their to of ache. people willing brow to don’t all Yes. Certainly agree glasses on but have to potential off to they're want that a the second feel part, that not or time, of reading tied headache the

coming think because don't So And wanted push we X% we and we being do tolerability, as the We we drops, forward itself, generic up dose can the on that. an see with choose worry reducing medication. to unlike to didn't efficacy a have with without about we as we're pretty intermediate there. if substituted could because did X% clean we looking far to and in dose eye

easily X% with I could an drop a substituted glaucoma. be a if used and So X% I in for pilocarpine eye presbyopia, have pilocarpine I that's was

be for that and something worry will I cannot example, from pilocarpine, of to a about. because to go point But to that's around So a we that, how we in that not it's substituted way, need get I X.XX%, view. substitution avoid

Leonard Yaffe

Great. you. Thank

Sean Ianchulev

you. Thank

Operator

reached have to end Ianchulev session, call Sean closing And the we of I over remarks. for turn the will now question-and-answer and the

Sean Ianchulev

joining hope I Okay. has Thank update a everybody that today. us. forward first and again concludes financial in you. quarter look the May, XXXX you for We our Well, to call Thank good afternoon.

Operator

conference. today’s concludes This

You your this may you for at participation. time. disconnect your lines Thank

Eyenovia (EYEN) 26 Mar 212020 Q4 Earnings call transcript